HAEMONETICS CORP (HAE) Stock
3 members of Congress disclosed 9 trades in HAE since 2020: 6 purchases and 3 sales, most recently Lois Frankel (sale, May 7, 2021). 8 of the hedge funds AlphaScala tracks reported HAE in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $113.26M.
Which members of Congress traded HAEMONETICS CORP (HAE)?
Most recent: Lois Frankel (sale, May 7, 2021); records start May 15, 2020.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Lois Frankel D-FL · House | 2021-05-07 | sale | $1k – $15k |
| Lois Frankel D-FL · House | 2021-05-06 | partial sale | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2021-01-25 | sale | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2020-10-16 | purchase | $1k – $15k |
| Lois Frankel D-FL · House | 2020-08-14 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2020-06-01 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2020-05-28 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2020-05-19 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 20, 2026.
See all HAE political trades →Which hedge funds own HAE?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 1.51M | $113.26M | +485% |
| Millennium Management Israel Englander | 570K | $42.78M | +5730% |
| Renaissance Technologies Jim Simons (founder) | 130K | $9.75M | +201% |
| Point72 Steve Cohen | 109K | $8.19M | +92% |
| Bridgewater Associates Ray Dalio | 60K | $4.48M | +23% |
| D.E. Shaw David Shaw | 36K | $2.70M | -81% |
| Marshall Wace | 30K | $2.29M | -90% |
| Blackstone | 8K | $620.1K | +29% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →HAE price chart
Powered by TradingViewWhat does HAEMONETICS CORP do?
Haemonetics Corporation is a global healthcare company dedicated to providing innovative blood management solutions for organizations around the world. The company plays a crucial role in the healthcare industry by offering devices and services that aim to improve the quality, efficiency, and safety of blood supply. Haemonetics is known for its comprehensive portfolio, which includes blood collection and processing systems, plasma collection devices, and software solutions for blood centers and hospitals. The core focus of Haemonetics' offerings lies in enhancing blood donor and patient care, optimizing blood banks' operations, and ensuring the safety and availability of blood and blood components. It serves a wide array of sectors, including hospitals, blood centers, and plasma collection centers, facilitating the global demand for transfusion medicine. With its headquarters in Boston, Massachusetts, Haemonetics continues to influence the landscape of healthcare through its commitment to innovation and its significant contributions to enhancing blood management practices. By catering to a vital segment of the healthcare system, Haemonetics Corporation supports the delivery of essential medical treatments and therapies worldwide.